Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Amgen Obtains Buyout Financing; Quikrete Sets September Meeting

Amgen Inc. obtained bank commitments for as much as $1.65 billion to support its buyout of Onyx Pharmaceuticals Inc., while Quikrete Companies Inc. set a Sept. 10 lender meeting to discuss $1.62 billion of acquisition loans.

Bank of America Corp., JPMorgan Chase & Co. and Barclays Plc are arranging the transaction for the world’s largest biotechnology company by sales, Amgen said in a regulatory filing today. The acquisition, which has a purchase price of $10.4 billion or $9.7 billion net of estimated Onyx cash, will be financed using $8.1 billion in bank loans and cash the company has in the U.S., according to a statement yesterday distributed by PR Newswire.

Wells Fargo & Co. is arranging the financing for Quikrete to support its purchase of Custom Building Products Inc., according to a person with knowledge of the matter who asked not to be identified because terms aren’t set. The transaction includes a $1.23 billion term loan, a $190 million second-lien portion and a $200 million asset-backed piece.

Prices of leveraged loans fell 0.01 cent today to 97.66 cents on the dollar, according to the Standard & Poor’s/LSTA U.S. Leveraged Loan 100 Index. That’s the lowest since July 10.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.